Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes

US12054519B2 · kind B2 · utility

Assignees

• The United States of America as Represented by the Secretary, Dept. of Health and Human Services · US
• CODAGENIX INC. · US

Inventors

• Cyril Le Nouen · Bethesda, US
• Ursula Buchholz · Silver Spring, US
• Peter L. Collins · Kensington, US
• Steffen Mueller · Pforzheim, DE

Key dates

• Filing date: Jun 28, 2022
• Grant date: Aug 6, 2024
• Expiry date: Aug 23, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/00062
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K)L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.